Alnylam presents positive late-breaking data from ongoing phase 1 study of aln-agt, an investigational rnai therapeutic for the treatment of hypertension

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced today positive interim results from the ongoing phase 1 study of aln-agt, a subcutaneous investigational rnai therapeutic targeting liver-expressed angiotensinogen (agt) for the treatment of hypertension. results were presented during a late-breaking oral presentation at the 2021 joint meeting of the european society of hypertension (esh) and the international societ
ALNY Ratings Summary
ALNY Quant Ranking